Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Supernus Pharmaceuticals (SUPN) Long-Term Deferred Tax (2016 - 2026)

Supernus Pharmaceuticals has reported Long-Term Deferred Tax over the past 6 years, most recently at $38.4 million for Q4 2025.

Quarterly Long-Term Deferred Tax changed N/A to $38.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $38.4 million for FY2025, N/A changed from the prior year.
Long-Term Deferred Tax was $38.4 million for Q4 2025 at Supernus Pharmaceuticals, up from $8.8 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $38.4 million in Q4 2025 and troughed at $6.2 million in Q2 2025.